Navigation Links
Sangamo Announces Public Offering of Common Stock
Date:4/7/2011

gamo also has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to Sangamo's public offering of common stock, the anticipated timing of the closing of the offering, the research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including, risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC f
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
2. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
4. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
5. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
6. Sangamo BioSciences Announces Data Presentation of First In Vivo Demonstration of ZFN-mediated Gene Correction Via Systemic Delivery at American Society for Hematology Meeting
7. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
8. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
10. Sangamo BioSciences Announces Second Quarter 2010 Conference Call and Webcast
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
(Date:12/24/2014)... and NEW YORK , Dec. ... biopharmaceutical company advancing patient care in critical areas, announced the ... common stock, and warrants to purchase up to an aggregate ... $4.00 per share and $.01 per warrant.  The warrants have ...
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... Keck Graduate Institute,s (KGI) Biotechnology Entrepreneurship program today announced ... Dec. 8, 2008. , , ... individual investors who fund early-stage, technology and high-growth companies in ... in becoming angel investors. The educational session begins at ...
... disease,diagnostics market has demonstrated sustained growth due to ... occurring in the,market, promoting technology and product integration. ... policies for autoimmune diagnostic tests,persists, posing a challenge ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , ...
... JOSE, Calif., Nov. 21 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... minimally invasive treatment of venous reflux disease, today announced its,plans ... to be,held December 2-3, 2008, at The New York Palace ... Brian Farley, President and Chief Executive,Officer. , ...
Cached Biology Technology:KGI Entrepreneur Program Hosts Angel Investing Educational Meeting 2Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market 2Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market 3
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... found for the first time in a variety of freshwater ... , According to experts at the Aquatic Animal Health ... septicemia virus (VHSV), which causes fatal anemia and hemorrhaging in ... poses no threat to humans. , In May ...
... at the University of California, San Diego and three other ... inter-related responses that cells use to avoid becoming diseased or ... The group led by UCSD bioengineering professor Trey Ideker describe ... of gene control that is triggered by chemical damage to ...
... Iranian scientists have linked a chemical that plays an ... damage and male infertility, the 22nd annual conference of ... , Dr Iraj Amiri, embryology laboratory director at the ... years nitric oxide (NO) has been recognised as a ...
Cached Biology News:Cornell researchers find serious fish virus in Northeast for first time 2Heal thyself: Systems biology model reveals how cells avoid becoming cancerous 2Heal thyself: Systems biology model reveals how cells avoid becoming cancerous 3Study links high levels of nitric oxide to infertility and sperm DNA damage 2
... Kit ADAM17 Activity Kit TNF-α Converting Enzyme ... FROM LIGHT. AVOID FREEZE/THAW CYCLES. The InnoZyme™ ... sensitive assay designed to measure human TACE ... and for screening enzyme inhibitors. An Anti-Human ...
... GELase™ Agarose Gel-Digesting Preparation contains a unique ... simple, quantitative recovery of intact DNA and ... gels following electrophoresis in TAE, TBE, MOPS, ... digested directly in the TAE, TBE, MOPS, ...
... Premixed solution for high PCR specificity ... the combination of enzyme with unique ... nonspecific amplification provided by the ... handling convenient Master Mix and ...
Recombinant Cat Interferon Alpha Activity: 2.7 x 10 7 u/mg...
Biology Products: